Literature DB >> 31444571

[Proarrhythmic adverse effects of nonarrhythmic drugs].

C G Jungbauer1, L S Maier2.   

Abstract

Acquired QT prolongation is almost exclusively the result of inhibition of the potassium channel Ikr. Especially hospitalized patients have a high risk to suffer from Torsade de points (TdP). Therefore, any prescription of drugs with the potential for QT prolongation should involve the consideration of the necessity of the agent and interaction with other QT prolonging drugs. The website www.crediblemed.com helps to identify the risk for TdP of each drug. During drug prescription, it is necessary to monitor QTc with regular ECGs; QTc prolongation >500 ms or QTc increase >60 ms should trigger end of drug administration followed by monitoring of the patient according to the individual risk for TdP.

Entities:  

Keywords:  Acquired QT prolongation; Drug-related side effects and adverse reactions; Long QT syndrome; Potassium channel; Torsade de points tachycardia

Mesh:

Substances:

Year:  2019        PMID: 31444571     DOI: 10.1007/s00399-019-00635-0

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  27 in total

Review 1.  Novel insights in the congenital long QT syndrome.

Authors:  Xander H T Wehrens; Marc A Vos; Pieter A Doevendans; Hein J J Wellens
Journal:  Ann Intern Med       Date:  2002-12-17       Impact factor: 25.391

Review 2.  Drug induced QT prolongation and torsades de pointes.

Authors:  Yee Guan Yap; A John Camm
Journal:  Heart       Date:  2003-11       Impact factor: 5.994

3.  QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS.

Authors:  A SELZER; H W WRAY
Journal:  Circulation       Date:  1964-07       Impact factor: 29.690

4.  Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.

Authors:  K Ohnishi; H Yoshida; K Shigeno; S Nakamura; S Fujisawa; K Naito; K Shinjo; Y Fujita; H Matsui; A Takeshita; S Sugiyama; H Satoh; H Terada; R Ohno
Journal:  Ann Intern Med       Date:  2000-12-05       Impact factor: 25.391

5.  Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes.

Authors:  Ping Yang; Hideaki Kanki; Benoit Drolet; Tao Yang; Jian Wei; Prakash C Viswanathan; Stefan H Hohnloser; Wataru Shimizu; Peter J Schwartz; Marshall Stanton; Katherine T Murray; Kris Norris; Alfred L George; Dan M Roden
Journal:  Circulation       Date:  2002-04-23       Impact factor: 29.690

Review 6.  Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.

Authors:  M D Drici; N Clément
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

7.  Effect of arsenic trioxide on QT interval in patients with advanced malignancies.

Authors:  Jean T Barbey; John C Pezzullo; Steven L Soignet
Journal:  J Clin Oncol       Date:  2003-10-01       Impact factor: 44.544

Review 8.  Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors.

Authors:  David Zeltser; Dan Justo; Amir Halkin; Vitaly Prokhorov; Karin Heller; Sami Viskin
Journal:  Medicine (Baltimore)       Date:  2003-07       Impact factor: 1.889

9.  Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents.

Authors:  Benoit Drolet; Chantale Simard; Dan M Roden
Journal:  Circulation       Date:  2003-12-22       Impact factor: 29.690

10.  QTc interval prolongation associated with intravenous methadone.

Authors:  Craig A Kornick; Michael J Kilborn; Juan Santiago-Palma; Glenn Schulman; Howard T Thaler; Deborah L Keefe; Alexander N Katchman; John C Pezzullo; Steven N Ebert; Raymond L Woosley; Richard Payne; Paolo L Manfredi
Journal:  Pain       Date:  2003-10       Impact factor: 6.961

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.